Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00655993 · ClinicalTrials.gov registry record · Phase 1

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

A Phase 1 study of Inflammation and COPD, sponsored by VA Loma Linda Health Care System.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00655993 is a Phase 1 study of Inflammation and COPD that has completed, run by VA Loma Linda Health Care System. The registered enrollment target is 30 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00655993, a Phase 1 study of Inflammation and COPD, has completed, sponsored by VA Loma Linda Health Care System.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

Conditions Studied

Interventions

  • DRUG simvastatin

Study Locations (1)

California

  • VA Loma Linda Health Care System - Loma Linda

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-04
Est. Completion 2014-08
Phase Phase 1

Sponsor

VA Loma Linda Health Care System

5 total trials

What the Registry Record Tells You About NCT00655993

The ClinicalTrials.gov registry entry for NCT00655993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower). The listed sponsor is VA Loma Linda Health Care System, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which simvastatin is the first listed.

NCT00655993 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00655993 about?

NCT00655993 is a clinical study titled "Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)". Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

What is the current status of trial NCT00655993?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-04. Estimated completion is 2014-08.

What conditions does trial NCT00655993 study?

This clinical trial studies the following conditions: Inflammation, COPD.

What interventions are being tested in trial NCT00655993?

The interventions under investigation include: simvastatin (DRUG).

Who is sponsoring clinical trial NCT00655993?

This trial is sponsored by VA Loma Linda Health Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00655993 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.